Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 4, 2025

Earnings live: Ulta stock pops, HPE falls with guidance in focus, UiPath stock skyrockets

View original at finance.yahoo.com
Earnings live: Ulta stock pops, HPE falls with guidance in focus, UiPath stock skyrockets The third quarter earnings season is winding down, and only a handful of major companies have yet to report results…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Companies that beat earnings saw 0.4% average stock increase in four-day period, less than five-year average of 0.9%

    80% confidence
  • Many consumers' wallets are pressured and they are seeking value during the holiday season

    80% confidence
  • AI clusters are now measured in hundreds of thousands and soon millions of GPUs, pushing every aspect of interconnect

    80% confidence
  • Analysts are expecting a 13.4% jump in earnings per share during Q3 2025, marking the fourth straight quarter of double-digit earnings growth

    80% confidence
  • All consumers are seeking value, and marrying value-seeking behavior with convenience and discovery is where Dollar Tree thrives

    80% confidence
  • 3 million more households are now part of Dollar Tree's customer base compared to last year, with high-income consumers making up the majority of new customers

    80% confidence
  • Sentiment toward food retailers has soured over the past few months, including for Kroger

    80% confidence
  • Companies that miss earnings decreased by 5% on average during same period, well below five-year average decrease of 2.6%

    80% confidence
  • The Street is underestimating the growth potential for CrowdStrike as a beneficiary of the AI Revolution

    80% confidence
  • Enterprises want AI that can work within their secure data environments without compromise, and this partnership brings Claude into Snowflake where data already lives

    80% confidence
  • The consumer and competitive environment has grown notably tougher for food retailers like Kroger

    80% confidence
  • Five Below has seen nice traffic growth and growth in both new customers and retention

    80% confidence
  • The Celestial AI acquisition further strengthens Marvell's position at the forefront of one of the fastest-growing opportunities in AI datacenter infrastructure

    80% confidence
  • Ulta is confident in their holiday plans and teams are ready to drive excitement and deliver for guests

    80% confidence
  • Strong momentum has continued into Q4, including an excellent start to the holiday season with a record-breaking Thanksgiving weekend

    80% confidence
  • Q3 sales were the strongest in 13 quarters, reflecting the acceleration of Bold New Chapter strategy and demonstrating that changes are resonating with customers

    80% confidence
  • Q3 was an exceptional quarter with existing customers expanding and strong net-new customer additions

    80% confidence
  • What's worked for growth is expansion of the idea of what value looks like, with attention to items above $5 at $7, $10, $15

    80% confidence
  • These are the strongest quarterly results in Credo's history, reflecting the continued build-out of the world's largest AI training and inference clusters

    80% confidence

Data points we hold from this source

Snowflake Inc. · loss per share-0.87 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com